Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome.

Clin Gastroenterol Hepatol

Division of Gastroenterology, Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York 14215, USA.

Published: May 2010

Background & Aims: Cognitive behavior therapy (CBT) is an empirically validated treatment for irritable bowel syndrome (IBS), yet it is unclear for whom and under what circumstances it is most effective. We investigated whether patients who achieved a positive response soon after CBT onset (by week 4), termed rapid responders (RRs), maintain treatment gains compared with non-rapid responders. We also characterized the psychosocial profile of RRs on clinically relevant variables (eg, health status, IBS symptom severity, distress).

Methods: The study included 71 individuals (age, 18-70 y) whose IBS symptoms were consistent with Rome II criteria and were of at least moderate severity. Patients were assigned randomly to undergo a wait list control; 10 weekly 1-hour sessions of CBT; or four 1-hour CBT sessions over 10 weeks. RRs were classified as patients who reported adequate relief of pain, adequate relief of bowel symptoms, and a decrease in total IBS severity scores of 50 or greater by week 4.

Results: Of patients undergoing CBT, 30% were RRs; 90% to 95% of the RRs maintained gains at the immediate and 3-month follow-up examinations. Although the RRs reported more severe IBS symptoms at baseline, they achieved more substantial, sustained IBS symptom reduction than non-rapid responders. Both dosages of CBT had comparable rates of RR.

Conclusions: A significant proportion of IBS patients treated with CBT have a positive response within 4 weeks of treatment; these patients are more likely to maintain treatment gains than patients without a rapid response. A rapid response is not contingent on the amount of face-to-face contact with a clinician.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144205PMC
http://dx.doi.org/10.1016/j.cgh.2010.02.007DOI Listing

Publication Analysis

Top Keywords

rapid response
12
cognitive behavior
8
behavior therapy
8
patients
8
irritable bowel
8
bowel syndrome
8
positive response
8
maintain treatment
8
treatment gains
8
non-rapid responders
8

Similar Publications

Electrochemical Biosensors for Cancer Diagnosis: Multitarget Analysis to Present Molecular Characteristics of Tumor Heterogeneity.

JACS Au

December 2024

Center for Molecular Recognition and Biosensing, Shanghai Engineering Research Center of Organ Repair, Joint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Sciences, Shanghai University, Shanghai 200444, China.

Electrochemical biosensors are gaining attention as powerful tools in cancer diagnosis, particularly in liquid biopsy, due to their high efficiency, rapid response, exceptional sensitivity, and specificity. However, the complexity of intra- and intertumor heterogeneity, with variations in genetic and protein expression profiles and epigenetic modifications, makes electrochemical biosensors susceptible to false-positive or false-negative diagnostic outcomes. To address this challenge, there is growing interest in simultaneously analyzing multiple biomarkers to reveal molecular characteristics of tumor heterogeneity for precise cancer diagnosis.

View Article and Find Full Text PDF

Introduction: In recent years, the frequency and intensity of natural disasters and public emergencies around the world have been steadily increasing. Emergency logistics plays an irreplaceable role in providing rapid material and service support in the aftermath of disasters. Therefore, systematically analyzing the differences in emergency logistics responsiveness across various regions of China and understanding their underlying causes are of great significance for optimizing emergency logistics systems and improving disaster responsiveness.

View Article and Find Full Text PDF

First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report.

Ther Adv Neurol Disord

December 2024

Department of Neurology, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg 86156, Germany.

In acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), neonatal Fc-receptor (FcRn) inhibition has broadened the therapeutic spectrum. Myasthenic crisis (MC), heralded by an impending myasthenic crisis (iMC), is a critical condition requiring treatments with rapid onset and sustained efficacy. Currently treatments used for iMC, including intravenous immunoglobulins and plasma exchange/immunoadsorption, have limitations, such as delayed onset of action and potential side effects.

View Article and Find Full Text PDF

The COVID-19 pandemic presented unparalleled challenges to prompt and adaptive responses from nations worldwide. This review examines China's multifaceted approach to the crisis, focusing on five key areas of response: infrastructure and system design, medical care and treatment, disease prevention and control, economic and social resilience, and China's engagement in global health. This review demonstrates the effectiveness of a top-down command system at the national level, intersectoral coordination, a legal framework, and public social governance.

View Article and Find Full Text PDF

Background Combining left atrial appendage closure with catheter ablation (LAACCA) has been proposed as a potential approach to improving outcomes by simultaneously addressing arrhythmia and reducing stroke risk. This study compares the in-hospital outcomes of LAACCA vs. catheter ablation (CA) alone for atrial fibrillation (AFib) in patients with heart failure with reduced ejection fraction (HFrEF).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!